Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Dose-Response Effects of a 6-Week Progressive Resistance Training Program on Premenstrual Syndrome in Adolescent Girls

10 augusti 2026 uppdaterad av: Riphah International University
This study examines the dose-response effects of a 6-week progressive resistance training program on premenstrual syndrome (PMS) in adolescent girls. PMS is a common condition that affects physical, psychological, and social well-being. While exercise is known to reduce symptoms, the optimal intensity of resistance training remains unclear. Using a randomized controlled trial design, participants are assigned to progressive or low-intensity training groups. PMS symptoms and quality of life are assessed over time. The study aims to determine whether higher exercise intensity leads to greater symptom reduction and improved overall well-being.

Studieöversikt

Detaljerad beskrivning

This study focuses on premenstrual syndrome (PMS), a common cyclical condition experienced by adolescent girls that includes physical, psychological, and behavioral symptoms such as pain, mood swings, anxiety, fatigue, and reduced concentration. These symptoms can negatively affect academic performance, social interactions, and overall quality of life. Exercise has been shown to improve hormonal balance, reduce stress, and enhance mood through the release of endorphins and serotonin. However, most existing research has focused on aerobic exercise, with limited attention given to resistance training. Resistance training, which involves strengthening muscles through weights or bodyweight exercises, may offer additional benefits, but its optimal intensity and effectiveness for PMS management remain unclear. This study addresses this gap by examining the dose-response relationship of resistance training.

Studietyp

Interventionell

Inskrivning (Beräknad)

32

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Federal
      • Islamabad, Federal, Pakistan, 051
        • Rekrytering
        • Kens college model town humak and community model town
        • Kontakt:
      • Islamabad, Federal, Pakistan, 051
        • Rekrytering
        • Kid city high school
        • Kontakt:
        • Huvudutredare:
          • Amina Rizwan, MSPT(WH)

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  1. Diagnosed with Premenstrual Syndrome (PMS) based on PSST screening tool.
  2. Not currently engaged in any structured resistance or exercise training program.
  3. Medically cleared to participate in moderate-intensity resistance training.
  4. Provided written informed consent for participation.

Exclusion Criteria:

  1. Current use of hormonal therapy or oral contraceptives.
  2. History of endocrine disorders (e.g., PCOS, thyroid dysfunction).
  3. Any musculoskeletal or cardiovascular condition limiting exercise participation.
  4. Ongoing psychiatric medication or diagnosed depression/anxiety disorder.
  5. Participation in a structured exercise or resistance training program within the last 3 months.
  6. Use of analgesics, anti-inflammatory, or hormonal medications during the study period.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Progressive Resistance Training Group
Participants allocated to this arm will receive a supervised 6-week progressive resistance training program performed three times per week on non-consecutive days. Each session will last 45-60 minutes.

A supervised progressive resistance training program delivered three sessions per week for six weeks. Exercise intensity is gradually increased using the Borg Rating of Perceived Exertion (RPE) scale.

A warm up session will be done before resistance training exercise and Cool down for 5-10 minutes will be done exercise.

Participants will follow the FITT prescription for their resistance exercises.

Week 1-2 (DOSE 1) Intensity: Low. Bodyweight or dumbbells (RPE 7-11/20). Sets & Reps: 2 sets of 25-30 reps. Volume: High. Focus on mastering technique. Week 3-4 (DOSE 2) Intensity: moderate. Bodyweight or dumbbells (RPE 12-14/20). Sets & Reps: 2 sets of 20-25 repetitions. Volume: Moderate. Focus on mastering technique. Week 5-6(DOSE 3) Intensity: high. Dumbbells (RPE 15-16/20). Sets & Reps: 2 sets of 15-20 repetitions. Volume: Low.

Aktiv komparator: Low-Intensity Resistance Training Group
Participants allocated to this arm will receive a supervised low-intensity resistance training program for six weeks. Sessions will be conducted three times per week, lasting 45-60 minutes each. Participants will perform the same standardized resistance exercises as the experimental group; however, exercise intensity will remain low throughout the intervention without progressive overload.

Participants of this group will receive the same standardized exercises as the experimental group. Exercise intensity remains constant at low intensity throughout the intervention period without progressive increase.

Before exercise the participants will perform warm up and after exercise they will perform cool down, same as the experimental group.

The FITT protocol for this group is as following:

Week 1-2 (DOSE1) Intensity: low Body weight. or Dumbbells (RPE 7-11/20). Sets & Reps: 2 sets of 15repetitions. Volume: Low. Focus on mastering technique. Week 3-4 (DOSE 2) Intensity: low. Bodyweight or dumbbells (RPE 7-11/20). Sets & Reps: 2 sets of 20 repetitions. Volume: Moderate. Focus on mastering technique Week 5-6(DOSE 3) Intensity: Low. Bodyweight or dumbbells (RPE 7-11/20). Sets & Reps: 2 sets of 25 reps. Volume: High. Focus on mastering technique.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Premenstrual Symptoms Screening Tool (PSST)
Tidsram: Assessments will be conducted at baseline, week 2, week 4, week 6, and at 3-month follow-up
The primary outcome of this study is the severity of premenstrual syndrome symptoms, measured using the Premenstrual Symptoms Screening Tool (PSST). The PSST is a self-reported questionnaire used to assess physical, psychological, and behavioral symptoms related to PMS, including mood swings, irritability, anxiety, fatigue, bloating, breast tenderness, and difficulty concentrating. It also evaluates how these symptoms affect daily activities, school performance, and social relationships. Each item is scored on a 4-point Likert scale ranging from "none" to "severe." Higher scores indicate greater PMS severity..
Assessments will be conducted at baseline, week 2, week 4, week 6, and at 3-month follow-up

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Quality of Life (QoL)
Tidsram: Quality of life will be assessed at baseline, immediately after the 6-week intervention, and at 3-month follow-up using the WHOQOL-BREF questionnaire.
Quality of life will be assessed using the World Health Organization Quality of Life Questionnaire (WHOQOL-BREF). This questionnaire contains 26 items and evaluates four domains: physical health, psychological health, social relationships, and environmental well-being. Each item is rated on a 5-point Likert scale, with higher scores representing better quality of life. The WHOQOL-BREF is a reliable and valid tool commonly used in clinical and research settings to assess overall well-being.
Quality of life will be assessed at baseline, immediately after the 6-week intervention, and at 3-month follow-up using the WHOQOL-BREF questionnaire.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Rida Zafar, WHPT, Riphah International University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 augusti 2026

Primärt slutförande (Beräknad)

1 november 2026

Avslutad studie (Beräknad)

1 januari 2027

Studieregistreringsdatum

Först inskickad

5 augusti 2026

Först inskickad som uppfyllde QC-kriterierna

5 augusti 2026

Första postat (Faktisk)

10 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 augusti 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

IPD will not be shared to ensure participant confidentiality and data protection, particularly because the study involves adolescent girls, and data was collected for specific research purposes only."

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera